Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

ClinicalTrials.gov ID: NCT03203642

Public ClinicalTrials.gov record NCT03203642. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects With Autosomal Dominant Polycystic Kidney Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of the study was to compare and evaluate safety and efficacy of tesevatinib 50 milligrams (mg) versus placebo in participants with autosomal dominant polycystic kidney disease (ADPKD).

Study identification

NCT ID: NCT03203642
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Kadmon, a Sanofi Company; Industry
Enrollment: 80 participants

Conditions and interventions

Conditions

Interventions

Tesevatinib Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 60 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 12, 2017 (Actual)
Primary completion: Jan 25, 2022 (Actual)
Completion: Jan 25, 2022 (Actual)
Last update posted: Feb 6, 2023

2017 – 2022

United States locations

U.S. sites: 19
U.S. states: 14
U.S. cities: 18

Facility	City	State	ZIP	Site status
University of California San Diego	La Jolla	California	92037	—
California Institute for Renal Research	La Mesa	California	91942	—
University of California Los Angeles	Los Angeles	California	90095	—
University of California San Francisco	San Francisco	California	94143	—
University of Colorado Denver	Aurora	Colorado	80045	—
Yale Nephrology Clinical Research	New Haven	Connecticut	06520	—
Coastal Nephrology Associates Research Center, LLC	Port Charlotte	Florida	33952	—
Genesis Clinical Research	Tampa	Florida	33614	—
Emory University School of Medicine	Atlanta	Georgia	30322	—
University of Maryland	Baltimore	Maryland	21201	—
Tufts Medical Center	Boston	Massachusetts	02111	—
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02215	—
Mayo Clinic	Rochester	Minnesota	55905	—
Washington University	St Louis	Missouri	63110	—
Rogosin Institute	New York	New York	10021	—
University of Pennsylvania	Philadelphia	Pennsylvania	19104	—
Baylor Scott & White Research Institute	Temple	Texas	10016	—
University of Virginia	Charlottesville	Virginia	22908	—
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03203642, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 6, 2023 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03203642 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →